DaVita reports Q1 adjusted EPS $2.38, consensus $1.95

Reports Q1 revenue $3.07B, consensus $3.03B. “Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence,” said Javier Rodriguez, CEO of DaVita.